Avzid-T 1.125

Avzid-T 1.125 Injection is a powerful Ceftazidime + Tazobactam injection designed to combat a wide range of bacterial infections, especially those caused by resistant organisms. This advanced formulation combines Ceftazidime 1000 mg, a third-generation cephalosporin antibiotic, with Tazobactam 125 mg, a beta-lactamase inhibitor that enhances the effectiveness of the antibiotic.

This broad-spectrum antibiotic injection works by inhibiting bacterial cell wall synthesis while preventing enzyme-mediated resistance. As a result, it is highly effective in treating infections of the respiratory tract, urinary tract, skin, intra-abdominal region, and bloodstream.

Key Benefits

• Enhanced antibacterial action with dual-drug synergy
• Effective against beta-lactamase producing bacteria
• Suitable for severe and hospital-acquired infections
• Trusted parenteral antibiotic therapy for rapid action

Common Uses

Avzid-T Injection is widely used in clinical settings for:

• Pneumonia and lower respiratory infections
• Urinary tract infections (UTIs)
• Skin and soft tissue infections
• Septicemia and intra-abdominal infections

Administration & Safety

This injectable antibiotic vial is administered under medical supervision, ensuring precise dosage and optimal results. Patients should follow their healthcare provider’s instructions carefully to avoid resistance or side effects. Mild reactions like nausea or injection site discomfort may occur.

Conclusion

Avzid-T 1.125 Injection stands out as a reliable ceftazidime tazobactam combination injection for managing complex bacterial infections. Its potent formulation ensures faster recovery and improved patient outcomes, making it a preferred choice in modern antimicrobial therapy.